IART Stock Forecast & Price Target

Integra Lifesciences is attractive because its cash generation has strengthened materially, with 3Q operating cash flow of $96M and free cash flow of $86M, while year-to-date OCF of just under $130M remains on track toward the $190-200M target. The completed $2.1B refinancing on Oct 19 extends maturities, adds covenant headroom, and supports deleveraging, with net debt down to about $1.5B and leverage improving to 3.8x from 4.1x at 2Q. Despite near-term revenue pressure from flooding and softer Tissue Reconstruction, the business still shows encouraging underlying momentum in Neurosurgery, plus a discounted valuation near 5x 2027 EPS of $2.37 that leaves room for upside as execution improves.

Integra Lifesciences is facing a fundamentally challenged setup because its 3Q performance was helped by improved free cash flow conversion, yet the business still absorbed a margin hit from lost revenue and profit tied to the Cincinnati flood, alongside slightly higher interest expense. FY26 guidance was reiterated at $1.634-$1.654B of revenue and $2.30-$2.40 in adjusted EPS, but the company still expects flat gross margin versus 2025 and only flat adjusted EBITDA year over year, underscoring limited near-term operating leverage. Management’s 2026-27 recovery thesis depends on regaining products and re-adoption after prior ship holds and recalls, but with an adjusted EBITDA margin near 20% versus a peer average around 29%, execution risk and uncertainty around share recapture justify a cautious stance.